Aaron Wealth Advisors LLC raised its holdings in 10x Genomics (NASDAQ: TXG) by 68.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,414 shares of the company's stock after acquiring an additional 26,884 shares during the quarter. Aaron Wealth Advisors
Shares of 10x Genomics (NASDAQ: TXG - Get Free Report) gapped up prior to trading on Tuesday after William Blair upgraded the stock from a market perform rating to an outperform rating. The stock had previously closed at $19.81, but opened at $21.00. 10x Genomics shares last traded at $20.9670, with a volume of 150,356 shares
• 10x Genomics shares are powering higher. What's fueling TXG momentum?
10x Genomics (NASDAQ: TXG - Get Free Report) has earned a consensus recommendation of "Hold" from the sixteen ratings firms that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and four have issued a buy recommendation on the company. The
Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way for its stablecoin domain.
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today The Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal atlas, starting in oncology and immunology tissue, designed to generate harmonized multi-omics patient data. A Strategic Partnership with 10x Genomics: Leveraging the Xenium spatial transcriptomics platform as the foundational partner for the launch, the initiative sets a new benchmark for reproducible, AI-ready data generation across leading research institutions worldwide.
10x Genomics is undervalued, with a BUY rating and 18% upside to a $20.47 target, driven by robust consumables growth. Consumables, comprising 83% of revenue, continue double-digit growth, offsetting post-COVID instrument sales normalization and supporting recurring revenue expansion. TXG maintains a dominant 34% market share in single-cell biology, reinforced by increasing academic mindshare and strategic partnerships to drive future penetration.
Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling consideration.
10x Genomics (NASDAQ: TXG - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings. Profitability This table compares 10x
- Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost-efficient - - Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine - SAN FRANCISCO, March 17, 2026 /PRNewswire/ -- PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the public release of the world's largest in vivo CRISPR atlas. The 8 million-cell, brain-wide dataset represents the largest known causal genomics resource generated directly in living tissue.
